Therapeutic Asset Ratings

136 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Rivoceranib HER2-negative Breast Cancer	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P3	B (60)
TRASTUZUMAB HER2-negative Breast Cancer	Fudan University	P3	B (60)
METHOTREXATE HER2-negative Breast Cancer	Fudan University	P4	B (58)
Famitinib HER2-negative Breast Cancer	Fudan University	P3	B (56)
Fluzoparib HER2-negative Breast Cancer	Fudan University	P3	B (56)
Niraparib HER2-negative Breast Cancer	Dantari, Inc.	P3	B (56)
Cytosin-Arabinosid HER2-negative Breast Cancer	Fudan University	P4	CCC (55)
Veliparib HER2-negative Breast Cancer	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	P2	CCC (55)
Alpelisib HER2-negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (54)
Trastuzumab Emtansine HER2-negative Breast Cancer	University of Chicago	P2	CCC (54)
DEXAMETHASONE HER2-negative Breast Cancer	MedSIR	P3	CCC (52)
Duloxetine HER2-negative Breast Cancer	European Organisation for Research and Treatment of Cancer - EORTC	P3	CCC (52)
Entinostat HER2-negative Breast Cancer	National Cancer Institute (NCI)	P3	CCC (52)
FUROSEMIDE HER2-negative Breast Cancer	European Organisation for Research and Treatment of Cancer - EORTC	P3	CCC (52)
PACLITAXEL TREVATIDE HER2-negative Breast Cancer	Angiochem Inc	P3	CCC (52)
Catequentinib HER2-negative Breast Cancer	Sun Yat-sen University	P2	CCC (52)
Dan-222 HER2-negative Breast Cancer	Dantari, Inc.	P2	CCC (52)
Dapagliflozin HER2-negative Breast Cancer	Yale University	P2	CCC (52)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER HER2-negative Breast Cancer	University of Chicago	P2	CCC (52)
Trastuzumab Deruxtecan HER2-negative Breast Cancer	Kristina A. Fanucci	P2	CCC (52)
Tucatinib HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (52)
utd1 HER2-negative Breast Cancer	Hunan Cancer Hospital	P2	CCC (52)
Zanidatamab HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (52)
Metformin HER2-negative Breast Cancer	The Methodist Hospital Research Institute	P2	CCC (51)
Zotatifin HER2-negative Breast Cancer	Jennifer Lee Caswell-Jin	P2	CCC (51)

Showing 26 to 50 of 136 assets

PreviousPage 2 of 6Next